Improving Antimicrobial-Prescribing in Emergency Departments
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03349567|
Recruitment Status : Recruiting
First Posted : November 21, 2017
Last Update Posted : October 9, 2018
|Condition or disease||Intervention/treatment||Phase|
|Anti-Bacterial Agents Respiratory Tract Infections||Behavioral: Audit-and-feedback||Not Applicable|
Using a quasi-experimental design, the study team will work collaboratively with ED providers in the Veterans Health Administration (VHA) to improve antimicrobial-prescribing. Academic-detailing and an audit-and-feedback intervention will be implemented. Through audit-and-feedback, providers will be shown how their antimicrobial-prescribing compares to their peers, thereby encouraging them to consider their professional reputation when making prescribing decisions.
The study will use a pretest-posttest design (quasi-experimental design with a non-equivalent control group) to assess the effect of our pilot intervention at 2 participating EDs and 2 control EDs. For each ED, the pretest period will be the 12 months prior to the intervention. The intervention itself will last 12 months.
There will be an estimated 30 ED providers at the 2 study sites and 30 ED providers at the 2 control sites. Only antimicrobial prescriptions to patients discharged from the ED will be evaluated.
The primary outcome will be antimicrobial-prescribing volume adjusted for the total number of patient-visits. Secondary outcomes include the frequency of guideline-discordant antimicrobial-prescribing and adverse events.
At the conclusion of the pilot trial, a quasi-experimental interrupted time-series (ITS) analysis will be performed to assess the change in monthly antimicrobial usage for the 2 intervention sites combined and the 2 control sites combined. The time frame for this ITS analysis will be the one-year prior to the pilot trial's initiation through the trial's 1-year intervention period for a total of 24 months. In addition, a multivariable analysis will be performed to identify predictors of guideline-discordant therapy.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Health Services Research|
|Official Title:||The Use of Audit-and-Feedback to Improve Antimicrobial-Prescribing in Emergency Departments: a Quasi-experimental Study|
|Actual Study Start Date :||October 9, 2018|
|Estimated Primary Completion Date :||October 31, 2019|
|Estimated Study Completion Date :||December 31, 2019|
The experimental arm will consist of Emergency Department providers who do receive the intervention.
We will monitor the antimicrobial-prescribing of providers in the experimental arm. Our study team will meet with providers in the experimental arm to provide guidance on optimal antimicrobial-prescribing. We will provide personalized feedback to providers in the experimental arm once every quarter.
Other Name: Academic detailing
No Intervention: Control
The control arm will consist of providers who do not receive the intervention.
- Change in antimicrobial-prescribing volume [ Time Frame: Change in antimicrobial-prescribing volume will be calculated across the 12-months of the intervention period in comparison to the 12-months of the pre-intervention period. An interrupted time-series analysis will be performed. ]Antimicrobial-prescribing volume reflects the volume of antimicrobials prescribed per patient-visits. It is defined as the total number of antimicrobial prescriptions divided by the total number of patient-visits. This metric will be calculated on the provider level. It will also be calculated as an aggregate across all intervention sites and separately across all control sites.
- Guideline-discordant antimicrobial use [ Time Frame: It will be calculated for the entire 12-months of both the pre-intervention period and the intervention period. ]Guideline-discordant antimicrobial use is defined as the frequency of guideline-discordant antimicrobial-prescribing. To calculate this outcome, a trained chart abstractor will first manually review the medical records from a random sample of 25 visits for each provider. Visits that are audited will be associated with an ICD-10 code for an ARTI or cystitis.
- Late antimicrobial prescription [ Time Frame: It will be calculated for the entire 12-months of both the pre-intervention period and the intervention period. ]Late antimicrobial prescription is defined as the prescription of an (additional) antimicrobial by any provider within 30 days of the patient's index visit with the ED provider.
- Hospitalization [ Time Frame: It will be calculated for the entire 12-months of both the pre-intervention period and the intervention period. ]Hospitalization is defined as the need for hospitalization for any indication at a VA-facility within 30 days of the patient's index visit with the ED provider.
- Mortality [ Time Frame: It will be calculated for the entire 12-months of both the pre-intervention period and the intervention period. ]Mortality is defined as all-cause death within 30-days of the patient's index visit with the ED provider.
- Clostridium difficile [ Time Frame: It will be calculated for the entire 12-months of both the pre-intervention period and the intervention period. ]Clostridium difficile testing is defined as a laboratory test for Clostridium difficile ordered within 30-days of the patient's index visit with the ED provider. Clostridium difficile infection (CDI) is defined as a positive laboratory test for Clostridium difficile within 30-days of the patient's index visit with the ED provider.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03349567
|Contact: Daniel J Livorsi, MD||319-338-0581 ext firstname.lastname@example.org|
|Contact: Rajeshwair Nair, PhD, MBBS||319-338-0581 ext email@example.com|
|United States, Indiana|
|Richard Roudebush VAMC||Recruiting|
|Indianapolis, Indiana, United States, 46202|
|Contact: Andrew Dysangco|
|United States, South Dakota|
|Sioux Falls VA||Recruiting|
|Sioux Falls, South Dakota, United States, 57105|
|Contact: Daniel J Livorsi, MD|